Oregon Public Employees Retirement Fund Acquires 700 Shares of ADMA Biologics, Inc. (NASDAQ:ADMA)

Oregon Public Employees Retirement Fund increased its stake in shares of ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.3% during the 4th quarter, Holdings Channel reports. The fund owned 55,600 shares of the biotechnology company’s stock after acquiring an additional 700 shares during the period. Oregon Public Employees Retirement Fund’s holdings in ADMA Biologics were worth $954,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Illinois Municipal Retirement Fund acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $2,181,000. Bank of New York Mellon Corp raised its holdings in shares of ADMA Biologics by 10.8% during the fourth quarter. Bank of New York Mellon Corp now owns 1,521,166 shares of the biotechnology company’s stock valued at $26,088,000 after purchasing an additional 147,748 shares during the period. Y Intercept Hong Kong Ltd acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $510,000. Navellier & Associates Inc. acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $3,065,000. Finally, Handelsbanken Fonder AB acquired a new position in shares of ADMA Biologics during the fourth quarter valued at about $1,127,000. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Trading Up 6.2 %

ADMA opened at $16.39 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. ADMA Biologics, Inc. has a fifty-two week low of $5.08 and a fifty-two week high of $23.64. The firm has a market capitalization of $3.87 billion, a PE ratio of 58.54 and a beta of 0.75. The company’s 50-day moving average is $16.73 and its 200 day moving average is $17.98.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the stock. HC Wainwright upped their price objective on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Raymond James upped their price objective on shares of ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.